Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies.
Koc GH, Kok MR, Kasiem FR, Luime JJ, Tchetverikov I, Wilhelm-de Jong K, Korswagen LA, Denissen NHAM, Goekoop-Ruiterman YPM, Baudoin P, Kok P, Bos R, Dolhain RJEM, Vis M. Koc GH, et al. Among authors: goekoop ruiterman ypm. Lancet Rheumatol. 2026 Jan;8(1):e23-e32. doi: 10.1016/S2665-9913(25)00223-1. Epub 2025 Nov 20. Lancet Rheumatol. 2026. PMID: 41275881 Clinical Trial.
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis.
Koc GH, Kok MR, Snoeck Henkemans SVJ, Luime JJ, Tchetverikov I, van der Kaap JH, Baudoin P, Kok P, Goekoop-Ruiterman YPM, Vos PAJM, van Oosterhout M, Korswagen LA, Dolhain RJEM, Vis M; Cicero. Koc GH, et al. Among authors: goekoop ruiterman ypm. J Rheumatol. 2025 Jul 1;52(7):687-692. doi: 10.3899/jrheum.2024-1162. J Rheumatol. 2025. PMID: 40374510
Induction of Cure in Early Arthritis (I CEA): study protocol for an investigator-initiated randomized single-blind clinical trial with open-label extension to compare three treatment strategies in patients with newly diagnosed undifferentiated arthritis.
Bergstra SA, van Ouwerkerk L, Nevins IS, van der Pol JA, Helmich GS, Hest I, van Veen A, Bos R, Goekoop-Ruiterman YPM, Vonkeman HE, Bijsterbosch J, de Jong PHP, Güler-Yüksel M, Böhringer S, Huizinga TWJ, van Gaalen FA. Bergstra SA, et al. Among authors: goekoop ruiterman ypm. Trials. 2024 Nov 13;25(1):758. doi: 10.1186/s13063-024-08609-5. Trials. 2024. PMID: 39533416 Free PMC article.
PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
van de Laar CJ, Oude Voshaar MAH, Ten Klooster P, Tedjo DI, Bos R, Jansen T, Willemze A, Versteeg GA, Goekoop-Ruiterman YPM, Kroot EJ, van de Laar M. van de Laar CJ, et al. Among authors: goekoop ruiterman ypm. RMD Open. 2024 May 30;10(2):e004291. doi: 10.1136/rmdopen-2024-004291. RMD Open. 2024. PMID: 38816210 Free PMC article. Clinical Trial.
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis.
Kasiem FR, Kok MR, Luime JJ, Tchetverikov I, Korswagen LA, Denissen NHAM, Goekoop-Ruiterman YPM, van Oosterhout M, Fodili F, Hazes JMW, Tillett W, Vis M; CICERO. Kasiem FR, et al. Among authors: goekoop ruiterman ypm. RMD Open. 2023 Oct;9(4):e002972. doi: 10.1136/rmdopen-2022-002972. RMD Open. 2023. PMID: 37880177 Free PMC article.
52 results